GlassScriptPhysician profile
H Stephen Beyer
NPI 1518915800
$7,235.61
in general payments reported to CMS, 2019-2025
40 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2021: $287 · 2022: $1,051 · 2023: $1,127 · 2024: $1,900 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,551 · Travel and Lodging: $1,885 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.93 |
| Travel and Lodging | $1,885.27 |
| Education | $171.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,598.30 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $746.85 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $607.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $557.52 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $392.04 | 2022-2025 | Tepezza, Evenity, Repatha |
| Alexion Pharmaceuticals, INC. | $207.60 | 2022-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $193.82 | 2023-2025 | |
| Enterra Medical, INC. | $189.83 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.26 | 2022-2023 | |
| Esteve Pharmaceuticals LLC | $124.00 | 2025 | Metopirone |
| Pfizer INC. | $119.74 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $117.96 | 2025 | |
| Tandem Diabetes Care, INC. | $107.44 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $97.58 | 2024-2025 | Resmetirom, Rezdiffra |
| Novartis Pharmaceuticals Corporation | $87.12 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $85.57 | 2023-2025 | Synthroid |
| Kyowa Kirin, INC. | $79.43 | 2024-2025 | Crysvita |
| Recordati_rare_diseases_inc. | $74.55 | 2022-2025 | Isturisa |
| Mannkind Corporation | $73.22 | 2023-2025 | Afrezza |
| Esperion Therapeutics, INC. | $61.12 | 2021-2025 | Nexletol |
| Dexcom, INC. | $60.99 | 2023 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $49.97 | 2023-2024 | Inpefa |
| Xeris Pharmaceuticals, INC. | $48.94 | 2025 | Gvoke Hypopen |
| Chiesi USA, INC. | $43.68 | 2025 | Mycapssa |
| Insulet Corporation | $38.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.22 | 2023 | Jardiance |
| Eusa Pharma (US) LLC | $31.95 | 2022 | |
| Amryt Pharma Holdings LTD | $27.60 | 2022-2023 | Mycapssa |
| Ipsen Biopharmaceuticals, INC | $23.01 | 2022 | |
| Janssen Biotech, INC. | $20.39 | 2024 | Tremfya |
| Alvogen INC | $20.01 | 2025 | Teriparatide |
| Gilead Sciences, INC. | $19.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2025 | Gattex |
| Alcresta Therapeutics, INC. | $19.46 | 2024 | Relizorb |
| Radius Health, INC. | $19.01 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.71 | 2025 | Voquezna |
| Ibsa Pharma INC. | $17.74 | 2025 | Tirosint, Flector, Licart |
| Medtronic Minimed, INC. | $14.72 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.15 | 2022 | |
| Merck Sharp & Dohme LLC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.